Safety of nintedanib in real world in China: a non interventional study based on Idiopathic Pulmonary (Interstitial) Fibrosis Registry China Study (PORTRAY) data

Study identification

• EU PAS number:
  EUPAS49529
• Study ID:
  49530
• Official title and acronym:
  Safety of nintedanib in real world in China: a non interventional study based on Idiopathic Pulmonary (Interstitial) Fibrosis Registry China Study (PORTRAY) data
• DARWIN EU® study:
  No
• Study countries:
  China
• Study description:
  No information provided.
• Study status:
  Planned

Research institutions and networks

Institutions

China-Japan Friendship Hospital

Study timelines

Date when funding contract was signed

Planned:30/12/2022

Study start date

Planned:29/12/2023

Date of final study report

Planned:31/12/2026

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim (China) Investment Co., Ltd

Regulatory

• Was the study required by a regulatory body?:
  Unknown
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable